Pharmacology and immunology of botulinum toxin type A

被引：43

作者：

Aoki, KR ^{[1
]}

机构：

[1] Allergan Pharmaceut Inc, Irvine, CA 92612 USA

来源：

CLINICS IN DERMATOLOGY | 2003年 / 21卷 / 06期

关键词：

D O I：

10.1016/j.clindermatol.2003.11.006

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The utility of botulinum neurotoxins as therapeutic and esthetic agents depends on their ability to inhibit neurotransmitter release from selected neurons, remain localized at the site of injection, and evade the body's immunologic defenses. The clinical correlates of these actions, respectively, are efficacy, safety, and a low rate of antibody formation. These properties have long formed the basis for the use of botulinum toxin type A (BTX-A) in the treatment of movement disorders such as focal dystonias, spasticity, and cerebral palsy(1) and, more recently, in the treatment of glabellar line(2) -all of which are characterized by excessive muscle activity.

引用

收藏

页码：476 / 480

页数：5

相关论文

共 46 条

[1]

Aoki K R, 2001, J Neurol, V248 Suppl 1, P3

[2] Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety [J].

Aoki, KR .

TOXICON, 2002, 40 (07) :923-928

[3] A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice [J].

Aoki, KR .

TOXICON, 2001, 39 (12) :1815-1820

[4] Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study [J].

Binder, WJ ;

Brin, MF ;

Blitzer, A ;

Schoenrock, LD ;

Pogoda, JM .

OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2000, 123 (06) :669-676

[5] SELECTIVE LOCATION OF ACCEPTORS FOR BOTULINUM NEUROTOXIN-A IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS [J].

BLACK, JD ;

DOLLY, JO .

NEUROSCIENCE, 1987, 23 (02) :767-779

[6] INTERACTION OF I-125 LABELED BOTULINUM NEUROTOXINS WITH NERVE-TERMINALS .1. ULTRASTRUCTURAL AUTORADIOGRAPHIC LOCALIZATION AND QUANTITATION OF DISTINCT MEMBRANE ACCEPTORS FOR TYPE-A AND TYPE-B ON MOTOR NERVES [J].

BLACK, JD ;

DOLLY, JO .

JOURNAL OF CELL BIOLOGY, 1986, 103 (02) :521-534

[7] BOTULINUM NEUROTOXIN-A SELECTIVELY CLEAVES THE SYNAPTIC PROTEIN SNAP-25 [J].

BLASI, J ;

CHAPMAN, ER ;

LINK, E ;

BINZ, T ;

YAMASAKI, S ;

DECAMILLI, P ;

SUDHOF, TC ;

NIEMANN, H ;

JAHN, R .

NATURE, 1993, 365 (6442) :160-163

[8] HISTOLOGIC ASSESSMENT OF DOSE-RELATED DIFFUSION AND MUSCLE-FIBER RESPONSE AFTER THERAPEUTIC BOTULINUM-A TOXIN INJECTIONS [J].

BORODIC, GE ;

FERRANTE, R ;

PEARCE, LB ;

SMITH, K .

MOVEMENT DISORDERS, 1994, 9 (01) :31-39

[9] Treatment with botulinum toxin type B for upper-limb spasticity [J].

Brashear, A ;

McAfee, AL ;

Kuhn, ER ;

Ambrosius, WT .

ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2003, 84 (01) :103-107

[10] Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke [J].

Brashear, A ;

Gordon, MF ;

Elovic, E ;

Kassicieh, VD ;

Marciniak, C ;

Lee, CH ;

Jenkins, S ;

Turkel, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :395-400

← 1 2 3 4 5 →